Floatz logo

Therapeutic Asset Ratings

615 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Jskn003
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (53)
LENVATINIB
Advanced Colorectal Carcinoma
Fudan UniversityP2CCC (53)
LENVATINIB
Liver Metastasis
Fudan UniversityP2CCC (53)
Letrozole
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
Levoleucovorin
Intestinal Neoplasms
Fudan UniversityP2CCC (53)
Mecapegfilgrastim
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (53)
Mitoxantrone
Breast Neoplasm
Fudan UniversityP2CCC (53)
Mitoxantrone
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
Mitoxantrone
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
Mitoxantrone
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (53)
Orelabrutinib
Helicobacter Pylori Infection, Susceptibility To
Fudan UniversityP2CCC (53)
Orelabrutinib
Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Fudan UniversityP2CCC (53)
Pamiparib
Small Cell Lung Carcinoma
Fudan UniversityP2CCC (53)
Penpulimab
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (53)
PREDNISONE TABLETS
Maintenance Therapy
Fudan UniversityP2CCC (53)
Pyrotinib
Estrogen-Receptor Positive Breast Cancer
Fudan UniversityP2CCC (53)
Pyrotinib
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
Pyrotinib
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
qlc5513
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (53)
rc48
Cutaneous Paget Disease
Fudan UniversityP2CCC (53)
Retinoic Acid
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (53)
Rivoceranib
Advanced Colorectal Carcinoma
Fudan UniversityP2CCC (53)
Rivoceranib
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
Rivoceranib
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
S-1
Intestinal Neoplasms
Fudan UniversityP2CCC (53)
Showing 326 to 350 of 615 assets
PreviousPage 14 of 25Next